Phenylbutazone

Publisher Website
Google Scholar
Abstract
IN the treatment of chronic rheumatic diseases experience teaches that from a large selection of pharmacologic agents "many are called but few are chosen." Initial enthusiasm for new medications is usually tempered by prolonged clinical evaluation. Original therapeutic success may wane, or the incidence of toxic manifestations may increase. Progress reports are therefore desirable to determine whether a new drug merits a permanent place in the clinical armamentarium.In 1953 experience with phenylbutazone in the treatment of 800 patients with a variety of diseases was described.1 At that time this pyrazole was considered of greatest value in gout and useful, . . .

This publication has 3 references indexed in Scilit: